Login to Your Account



From 'Heron' out, pain combo phase II winner aiming at bupivacaine

By Randy Osborne
Staff Writer

Wednesday, September 23, 2015

What one analyst described as Heron Therapeutics Inc.'s "profound benefit" in phase II data with HTX-011 for post-bunionectomy pain triggered speculation about how the findings might translate into a pivotal trial with the compound.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription